64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- University of MichiganUS5 papers
- Eli Lilly (United States)US3 papers
- AbbVie (Japan)1 paper
- Amgen (United States)US1 paper
- Berkeley CollegeUS1 paper
- Boston UniversityUS1 paper
- Bristol-Myers Squibb (United States)US1 paper
- CSL (Switzerland)CH1 paper
- CSL (United States)US1 paper
- Day Kimball HealthcareUS1 paper
- Eli Lilly (Canada)CA1 paper
- Eli Lilly (Singapore)SG1 paper
Showing 2023Show all
2 papers · 1 filter
stat.ME2023
A Class of Computational Methods to Reduce Selection Bias when Designing Phase 3 Clinical Trials
Tianyu Zhan
When designing confirmatory Phase 3 studies, one usually evaluates one or more efficacious and safe treatment option(s) based on data from previous studies. However, several retros…
stat.ME2023★ 3 cited
Sensitivity Analysis for Unmeasured Confounding in Medical Product Development and Evaluation Using Real World Evidence
Yixin Fang, Pallavi Mishra-Kalyani, Xiang Zhang +8
The American Statistical Association Biopharmaceutical Section (ASA BIOP) scientific working group on real-world evidence (RWE) has been making continuous, extended efforts towards…